Amneal Pharmaceuticals, Inc. (AMRX) stock
AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3063% above fair value
$21.12−0.11 (-0.52%)
Close on Nov 17, 2026Market cap $6.74BP/E 43.1Yield –
Amneal Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Amneal Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $3.12B, up 9.3% year over year. For fiscal 2025 it was $3.02B, up 8.0% from the year before. The highest annual figure on record is $3.02B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.02B | +8.0% |
| FY2024 | Dec 31, 2024 | $2.79B | +16.7% |
| FY2023 | Dec 31, 2023 | $2.39B | +8.2% |
| FY2022 | Dec 31, 2022 | $2.21B | +5.7% |
| FY2021 | Dec 31, 2021 | $2.09B | +5.1% |
| FY2020 | Dec 31, 2020 | $1.99B | +22.5% |
| FY2019 | Dec 31, 2019 | $1.63B | -2.2% |
| FY2018 | Dec 31, 2018 | $1.66B | +60.9% |
| FY2017 | Dec 31, 2017 | $1.03B | +1.5% |
| FY2016 | Dec 31, 2016 | $1.02B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $796.20M | +9.9% |
| Q1 FY2026 | Mar 31, 2026 | $722.52M | +3.9% |
| Q4 FY2025 | Dec 31, 2025 | $814.32M | +11.5% |
| Q3 FY2025 | Sep 30, 2025 | $784.51M | +11.7% |
| Q2 FY2025 | Jun 30, 2025 | $724.51M | +3.2% |
| Q1 FY2025 | Mar 31, 2025 | $695.42M | +5.5% |
| Q4 FY2024 | Dec 31, 2024 | $730.52M | +18.4% |
| Q3 FY2024 | Sep 30, 2024 | $702.47M | +13.3% |
| Q2 FY2024 | Jun 30, 2024 | $701.78M | +17.1% |
| Q1 FY2024 | Mar 31, 2024 | $659.19M | +18.2% |
| Q4 FY2023 | Dec 31, 2023 | $616.98M | +1.2% |
| Q3 FY2023 | Sep 30, 2023 | $620.04M | +13.7% |
| Q2 FY2023 | Jun 30, 2023 | $599.05M | +7.1% |
| Q1 FY2023 | Mar 31, 2023 | $557.54M | +12.0% |
| Q4 FY2022 | Dec 31, 2022 | $609.76M | +13.6% |
| Q3 FY2022 | Sep 30, 2022 | $545.56M | +3.2% |
| Q2 FY2022 | Jun 30, 2022 | $559.36M | +4.5% |
| Q1 FY2022 | Mar 31, 2022 | $497.63M | +0.9% |
| Q4 FY2021 | Dec 31, 2021 | $536.90M | +5.3% |
| Q3 FY2021 | Sep 30, 2021 | $528.59M | +1.8% |
| Q2 FY2021 | Jun 30, 2021 | $535.08M | +15.2% |
| Q1 FY2021 | Mar 31, 2021 | $493.11M | -1.1% |
| Q4 FY2020 | Dec 31, 2020 | $510.03M | +28.4% |
| Q3 FY2020 | Sep 30, 2020 | $519.29M | +37.3% |
| Q2 FY2020 | Jun 30, 2020 | $464.66M | +14.8% |
| Q1 FY2020 | Mar 31, 2020 | $498.53M | +11.7% |
| Q4 FY2019 | Dec 31, 2019 | $397.33M | -20.1% |
| Q3 FY2019 | Sep 30, 2019 | $378.28M | -20.6% |
| Q2 FY2019 | Jun 30, 2019 | $404.64M | -2.2% |
| Q1 FY2019 | Mar 31, 2019 | $446.12M | +62.1% |
| Q4 FY2018 | Dec 31, 2018 | $497.53M | +69.6% |
| Q3 FY2018 | Sep 30, 2018 | $476.49M | +87.1% |
| Q2 FY2018 | Jun 30, 2018 | $413.79M | +59.2% |
| Q1 FY2018 | Mar 31, 2018 | $275.19M | +21.9% |
| Q4 FY2017 | Dec 31, 2017 | $293.37M | – |
| Q3 FY2017 | Sep 30, 2017 | $254.73M | – |
| Q2 FY2017 | Jun 30, 2017 | $259.87M | – |
| Q1 FY2017 | Mar 31, 2017 | $225.68M | – |
See a number that looks wrong?